Resistance analysis of the hepatitis C virus NS5A inhibitor BMS-790052 in an in vitro replicon system

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 9, 2010, Pages 3641-3650

  Fridell, Robert A ^a   Qiu, Dike ^a   Wang, Chunfu ^a   Valera, Lourdes ^a   Gao, Min ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTIVIRUS AGENT; BMS 790052; NONSTRUCTURAL PROTEIN 5A; PROTEINASE INHIBITOR; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; CELL LINE; CONTROLLED STUDY; DRUG POTENCY; DRUG STRUCTURE; GENE MUTATION; GENETIC VARIABILITY; GENOTYPE; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; PRIORITY JOURNAL; REPLICON;

ANTIVIRAL AGENTS; CELL LINE, TUMOR; DRUG RESISTANCE, VIRAL; GENOTYPE; HEPACIVIRUS; HUMANS; IMIDAZOLES; MUTATION; PHENOTYPE;

EID: 77956116880     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00556-10     Document Type: Article

References (38)

1. Asselah, T., Y. Benhamou, and P. Marcellin. 2009. Protease and polymerase inhibitors for the treatment of hepatitis C. Liver Int. 29(Suppl. 1):57-67.
2. Brass, V., E. Bieck, R. Montserret, B. Wolk, J. A. Hellings, H. E. Blum, F. Penin, and D. Moradpour. 2002. An amino-terminal amphipathic alphahelix mediates membrane association of the hepatitis C virus nonstructural protein 5A. J. Biol. Chem. 277:8130-8139.
3. Chevaliez, S., and J.-M. Pawlotsky. 2007. Hepatitis C virus: virology, diagnosis and management of antiviral therapy. World J. Gastroenterol. 13:2461-2466.
4. Combet, C., N. Garnier, C. Charavay, D. Grando, D. Crisan, J. Lopez, A. Dehne-Garcia, C. Geourjon, E. Bettler, C. Hulo, P. L. Mercier, R. Bartenschlager, H. Diepolder, D. Moradpour, J. M. Pawlotsky, C. M. Rice, C. Trepo, F. Penin, and G. Deléage. 2007. euHCVdb: the European hepatitis C virus database. Nucleic Acids Res. 35:D363-D366.
5. Elazar, M., P. Liu, C. M. Rice, and J. S. Glenn. 2004. An N-terminal amphipathic helix in hepatitis C virus (HCV) NS4B mediates membrane association, correct localization of replication complex proteins, and HCV RNA replication. J. Virol. 78:11393-11400.
6. Gao, M., R. E. Nettles, M. Belema, L. B. Snyder, V. N. Nguyen, R. A. Fridell, M. H. Serrano-Wu, D. R. Langley, J.-H. Sun, D. R. O'Boyle II, J. A. Lemm, C. Wang, J. O. Knipe, C. Chien, R. J. Colonno, D. M. Grasela, N. A. Meanwell, and L. G. Hamann. 2010. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical efficacy. Nature 465:96-100.
7. Hanoulle, X., D. Verdegem, A. Badillo, J. M. Wieruszeski, F. Penin, and G. Lippens. 2009. Domain 3 of non-structural protein 5A from hepatitis C virus is natively unfolded. Biochem. Biophys. Res. Commun. 38:634-638.
8. Higuchi, R. 1990. Recombinant PCR, p. 177-183. In M. A. Innis, D. H. Gelfand, J. John, J. J. Sninsky, and T. J. White (ed.), PCR protocols: a guide to methods and applications. Academic Press, San Diego, CA.
9. Hirashima, S., T. Suzuki, T. Ishida, S. Noji, S. Yata, I. Ando, M. Komatsu, S. Ikeda, and H. Hashimoto. 2006. Benzimidazole derivatives bearing substituted biphenyls as hepatitis C virus NS5B RNA-dependent RNA polymerase inhibitors: structure-activity relationship studies and identification of a potent and highly selective inhibitor JTK-109. J. Med. Chem. 49:4721-4736.
10. Huang, L., J. Hwang, S. D. Sharma, M. R. Hargittai, Y. Chen, J. J. Arnold, K. D. Raney, and C. E. Cameron. 2005. Hepatitis C virus non-structural protein 5A (NS5A) is an RNA binding protein. J. Biol. Chem. 280:36417-36428.
11. Huang, Y., K. Staschke, R. De Francesco, and S. L. Tan. 2007. Phosphorylation of hepatitis C virus NS5A nonstructural protein: a new paradigm for phosphorylation-dependent viral RNA replication? Virology 364:1-9.
12. Kieffer, T. L., A. D. Kwong, and G. R. Picchio. 2010. Viral resistance to specifically targeted antiviral therapies for hepatitis C (STAT-Cs). J. Antimicrob. Chemother. 65:202-212.
13. Kneteman, N. M., A. Y. Howe, T. Gao, J. Lewis, D. Pevear, G. Lund, D. Douglas, D. F. Mercer, D. L. Tyrrell, F. Immermann, I. Chaudhary, J. Speth, S. A. Villano, J. O'Connell, and M. Collett. 2009. HCV796: a selective nonstructural protein 5B polymerase inhibitor with potent anti-hepatitis C virus activity in vitro, in mice with chimeric human livers, and in humans infected with hepatitis C virus. Hepatology 49:745-752.
14. Le Guillou-Guillemette, H., S. Vallet, C. Gaudy-Graffin, C. Payan, A. Pivert, A. Goudeau, and F. Lunel-Fabiani. 2007. Genetic diversity of the hepatitis C virus: impact and issues in the antiviral therapy. World J. Gastroenterol. 13:2416-2426.
15. Lemm, J. A., D. R. O'Boyle II, M. Liu, P. T. Nower, R. Colonno, M. S. Deshpande, L. B. Snyder, S. W. Martin, D. R. St. Laurent, M. H. Serrano- Wu, J. L. Romine, N. A. Meanwell, and M. Gao. 2010. Identification of NS5A inhibitors. J. Virol. 84:482-491.
16. Lemm, J. A., M. Liu, R. E. Rose, R. Fridell, D. R. O'Boyle, R. Colonno, and M. Gao. 2005. Replication-competent chimeric hepatitis C virus subgenomic replicons. Intervirology 48:183-191.
17. Lemon, S. M., C. Walker, M. J. Alter, and M. Yi. 2007. Hepatitis C virus, p. 1254-1304. In D. M. Knipe et al. (ed.), Fields virology, 5th ed., vol. 1. Lippincott-Raven Publishers, Philadelphia, PA.
18. Liang, Y., H. Ye, C. B. Kang, and H. S. Yoon. 2007. Domain 2 of nonstructural protein 5A (NS5A) of hepatitis C virus is natively unfolded. Biochemistry 46:11550-11558.
19. Liu, S., I. H. Ansari, S. C. Das, and A. K. Pattnaik. 2006. Insertion and deletion analyses identify regions of non-structural protein 5A of hepatitis C virus that are dispensable for viral genome replication. J. Gen. Virol. 87: 323-327.
20. Lohmann, V., F. Körner, A. Dobierzewska, and R. Bartenschlager. 2001. Mutations in hepatitis C virus RNAs conferring cell culture adaptation. J. Virol. 75:1437-1449. (Pubitemid 32094702)
21. Lohmann, V., F. Körner, J. O. Koch, U. Herian, L. Theilmann, and R. Bartenschlager. 1999. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 285:110-113. (Pubitemid 29307577)
22. Love, R. A., O. Brodsky, M. J. Hickey, P. A. Wells, and C. N. Cronin. 2009. Crystal structure of a novel dimeric form of NS5A domain I protein from hepatitis C virus. J. Virol. 83:4395-4403.
23. Macdonald, A., and M. Harris. 2004. Hepatitis C virus NS5A: tales of a promiscuous protein. J. Gen. Virol. 85:2485-2502.
24. Magiorkinis, G., E. Magiorkinis, D. Paraskevis, S. Y. Ho, B. Shapiro, O. G. Pybus, J. P. Allain, and A. Hatzakis. 2009. The global spread of hepatitis C virus 1a and 1b: a phylodynamic and phylogeographic analysis. PLoS Med. 6:e1000198.
25. Moucari, R., and P. Marcellin. 2009. Hepatitis C: the role of new interferons in the era of STAT-C. Nat. Rev. Gastroenterol. Hepatol. 6:509-511.
26. O'Boyle, D. R., P. T. Nower, J. L. Lemm, L. Valera, J.-H. Sun, K. Rigat, R. Colonno, and M. Gao. 2005. Development of a cell-based highthroughput specificity screen using a hepatitis C virus-bovine viral diarrhea virus dual replicon assay. Antimicrob. Agents Chemother. 49:1346-1353.
27. Parfieniuk, A., J. Jaroszewicz, and R. Flisiak. 2007. Specifically targeted antiviral therapy for hepatitis C virus. World J. Gastroenterol. 13:5673-5681.
28. Penin, F., V. Brass, N. Appel, S. Ramboarina, R. Montserret, D. Ficheux, H. E. Blum, R. Bartenschlager, and D. Moradpour. 2004. Structure and function of the membrane anchor domain of hepatitis C virus nonstructural protein 5A. J. Biol. Chem. 279:40835-40843.
29. Sarrazin, C., and S. Zeuzem. 2010. Resistance to direct antiviral agents in patients with hepatitis C virus infection. Gastroenterology 138:447-462.
30. Schinazi, R. F., L. Bassit, and C. Gavegnano. 2010. HCV drug discovery aimed at viral eradication. J. Viral Hepat. 17:77-90.
31. Seiwert, S. D., S. W. Andrews, Y. Jiang, V. Serebryany, H. Tan, K. Kossen, P. T. Rajagopalan, S. Misialek, S. K. Stevens, A. Stoycheva, J. Hong, S. R. Lim, X. Qin, R. Rieger, K. R. Condroski, H. Zhang, M. G. Do, C. Lemieux, G. P. Hingorani, D. P. Hartley, J. A. Josey, L. Pan, L. Beigelman, and L. M. Blatt. 2008. Preclinical characteristics of the hepatitis C virus NS3/4A protease inhibitor ITMN-191 (R7227). Antimicrob. Agents Chemother. 52:4432-4441.
32. Shepard, C. W., L. Finelli, and M. J. Alter. 2005. Global epidemiology of hepatitis C virus infection. Lancet Infect. Dis. 5:558-567.
33. Simmonds, P. 2004. Genetic diversity and evolution of hepatitis C virus-15 years on. J. Gen. Virol. 85:3173-3188.
34. Tellinghuisen, T. L., J. Marcotrigiano, A. E. Gorbalenya, and C. M. Rice. 2004. The NS5A protein of hepatitis C virus is a zinc metalloprotein. J. Biol. Chem. 279:48576-48587.
35. Tellinghuisen, T. L., J. Marcotrigiano, and C. M. Rice. 2005. Structure of the zinc-binding domain of an essential component of the hepatitis C virus replicase. Nature 435:374-379.
36. Tellinghuisen, T. L., K. L. Foss, J. C. Treadaway, and C. M. Rice. 2008. Identification of residues required for RNA replication in domains II and III of the hepatitis C virus NS5A protein. J. Virol. 82:1073-1083.
37. Thompson, A. J., and J. G. McHutchison. 2009. Antiviral resistance and specifically targeted therapy for HCV (STAT-C). J. Viral Hepat. 16:377-387.
38. Thompson, A., K. Patel, H. Tillman, and J. G. McHutchison. 2009. Directly acting antivirals for the treatment of patients with hepatitis C infection: a clinical development update addressing key future challenges. J. Hepatol. 50:184-194.